Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer VCMap
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        

Generate Chart For    
    (Chart displayed below)
Rat Strains
{{sample.term}}
Measurement Methods
{{method.term}}
Age
{{ageRange}}
Experimental Conditions
     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1aCondition 1b
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days11CMO:0001400maximum body weight loss to initial body weight ratio9.6%1.44.6433MMO:0000016body weighing method0.0squalene (200 ul) 69795squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days14CMO:0001400maximum body weight loss to initial body weight ratio5.9%3.713.8441MMO:0000016body weighing method0.0Freund's complete adjuvant (100 ul) 69797Freund's complete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days14CMO:0001400maximum body weight loss to initial body weight ratio2.8%1.03.7417MMO:0000016body weighing method0.0type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69799type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days16CMO:0001400maximum body weight loss to initial body weight ratio8.8%2.28.8MMO:0000016body weighing method0.0pristane (150 ul) 69805pristane (150 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days16CMO:0001453percentage of study population developing experimental arthritis during a period of time69%MMO:0000163in vivo visual assessment0.0pristane (150 ul) 69718pristane (150 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days11CMO:0001453percentage of study population developing experimental arthritis during a period of time73%MMO:0000163in vivo visual assessment0.0squalene (200 ul) 69705squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days14CMO:0001453percentage of study population developing experimental arthritis during a period of time36%MMO:0000163in vivo visual assessment0.0Freund's complete adjuvant (100 ul) 69708Freund's complete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days14CMO:0001453percentage of study population developing experimental arthritis during a period of time71%MMO:0000163in vivo visual assessment0.0type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69711type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1301Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both0 days7CMO:0001453percentage of study population developing experimental arthritis during a period of time0%MMO:0000163in vivo visual assessment0.0Freund's incomplete adjuvant (200 ul) 84874Freund's incomplete adjuvant (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days11CMO:0001450post-insult time to onset of experimental arthritis16d0.41.3266MMO:0000163in vivo visual assessment0.0squalene (200 ul) 69774squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days14CMO:0001450post-insult time to onset of experimental arthritis13.6d0.41.4967MMO:0000163in vivo visual assessment0.0Freund's complete adjuvant (100 ul) 69776Freund's complete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days14CMO:0001450post-insult time to onset of experimental arthritis17.6d0.82.9933MMO:0000163in vivo visual assessment0.0type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69779type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both200 days to 120 days16CMO:0001450post-insult time to onset of experimental arthritis13.1d1.14.4MMO:0000163in vivo visual assessment0.0pristane (150 ul) 69786pristane (150 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both180 days to 120 days11CMO:0001466serum orosomucoid 1 level790mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assaysqualene (200 ul) 69752squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both180 days to 120 days14CMO:0001466serum orosomucoid 1 level370mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assayFreund's complete adjuvant (100 ul) 69755Freund's complete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both180 days to 120 days14CMO:0001466serum orosomucoid 1 level500mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assaytype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69758type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000227DA.PVG.1AV1-(D4Rat155-D4Rat84)both180 days to 120 days16CMO:0001466serum orosomucoid 1 level750mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assaypristane (150 ul) 69765pristane (150 ul)

Contact Us |  About Us |  Jobs at RGD